|
Originally published In Press as doi:10.1074/jbc.M511112200 on January 12, 2006
J. Biol. Chem., Vol. 281, Issue 11, 7437-7444, March 17, 2006
Selective Inhibition of Fibroblast Activation Protein Protease Based on Dipeptide Substrate Specificity*
Conrad Yap Edosada ,
Clifford Quan ,
Christian Wiesmann¶,
Thuy Tran ,
Dan Sutherlin ,
Mark Reynolds ,
J. Michael Elliott||,
Helga Raab||,
Wayne Fairbrother¶, and
Beni B. Wolf 1
From the
Departments of Molecular Oncology, Medicinal Chemistry, ¶Protein Engineering, and ||Protein Chemistry, Genentech, Inc., South San Francisco, California 94080
Fibroblast activation protein (FAP) is a transmembrane serine peptidase that belongs to the prolyl peptidase family. FAP has been implicated in cancer; however, its specific role remains elusive because inhibitors that distinguish FAP from other prolyl peptidases like dipeptidyl peptidase-4 (DPP-4) have not been developed. To identify peptide motifs for FAP-selective inhibitor design, we used P2-Pro1 and acetyl (Ac)-P2-Pro1 dipeptide substrate libraries, where P2 was varied and substrate hydrolysis occurs between Pro1 and a fluorescent leaving group. With the P2-Pro1 library, FAP preferred Ile, Pro, or Arg at the P2 residue; however, DPP-4 showed broad reactivity against this library, precluding selectivity. By contrast, with the Ac-P2-Pro1 library, FAP cleaved only Ac-Gly-Pro, whereas DPP-4 showed little reactivity with all substrates. FAP also cleaved formyl-, benzyloxycarbonyl-, biotinyl-, and peptidyl-Gly-Pro substrates, which DPP-4 cleaved poorly, suggesting an N-acyl-Gly-Pro motif for inhibitor design. Therefore, we synthesized and tested the compound Ac-Gly-prolineboronic acid, which inhibited FAP with a Ki of 23 ± 3 nM. This was 9- to 5400-fold lower than the Ki values for other prolyl peptidases, including DPP-4, DPP-7, DPP-8, DPP-9, prolyl oligopeptidase, and acylpeptide hydrolase. These results identify Ac-Gly-BoroPro as a FAP-selective inhibitor and suggest that N-acyl-Gly-Pro-based inhibitors will allow testing of FAP as a therapeutic target.
Received for publication, October 12, 2005
, and in revised form, December 15, 2005.
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at http://www.jbc.org) contains supplemental Table S1.
1 To whom correspondence should be addressed: Genentech, Inc., 1 DNA Way-MS42, South San Francisco, CA 94080. Tel.: 650-467-1954; Fax: 650-225-6327; E-mail: bbwolf{at}gene.com.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. M. LeBeau, W. N. Brennen, S. Aggarwal, and S. R. Denmeade
Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin
Mol. Cancer Ther.,
May 1, 2009;
8(5):
1378 - 1386.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-J. Lee, Y.-S. Chen, C.-Y. Chou, C.-H. Chien, C.-H. Lin, G.-G. Chang, and X. Chen
Investigation of the Dimer Interface and Substrate Specificity of Prolyl Dipeptidase DPP8
J. Biol. Chem.,
December 15, 2006;
281(50):
38653 - 38662.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|